A Phase 3 interventional study of ADX-102 1% Topical Dermal Cream (reproxalap) and Vehicle of ADX-102 Topical Dermal Cream in Sjogren-Larsson Syndrome, sponsored by Aldeyra Therapeutics, Inc.. Completed at 2 sites in United States. Open to participants aged 3 Years and older. Per ClinicalTrials.gov, last updated 2023-02-09.
Sponsored by Aldeyra Therapeutics, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A Phase 3 Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of ADX-102 1% Topical Dermal Cream in Subjects with Sjögren-Larsson Syndrome (SLS).
Aldeyra Therapeutics, Inc. is the lead sponsor of 35 studies on the registry; 1 is open to participants now.
Of its 29 completed or terminated interventional studies of FDA-regulated products, 25 (86%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: ADX-102 1% Topical Dermal Cream (reproxalap)
Drug: Vehicle of ADX-102 Topical Dermal Cream
ADX-102 1% Topical Dermal Cream administered approximately every 24 hours for 6 months.
Vehicle of ADX-102 Topical Dermal Cream administered approximately every 24 hours for 6 months.
Visual Index Ichthyosis Severity (VIIS) Scaling Score as Assessed by the Investigator in ADX-102 Treated Patients
Change from baseline using the Visual Index Ichthyosis Severity (VIIS) Scaling Score (0 = least, 4 = most), where a higher value represents a worse outcome, in ADX-102 treated patients
Time frame: Efficacy assessment period (Week 1 through Week 24), where Baseline is Day 1.
| Milestone | ADX-102 1% Topical Dermal Cream | Vehicle Topical Dermal Cream |
|---|---|---|
| Started | 7 | 4 |
| Completed | 6 | 3 |
| Not completed | 1 | 1 |
Change from baseline using the Visual Index Ichthyosis Severity (VIIS) Scaling Score (0 = least, 4 = most), where a higher value represents a worse outcome, in ADX-102 treated patients
| units on a scale | ADX-102 1% Topical Dermal Cream |
|---|---|
| Visual Index Ichthyosis Severity (VIIS) Scaling Score as Assessed by the Investigator in ADX-102 Treated Patients | -0.7 ± 0.22 |
Collected over The period of time when adverse events were collected was approximately 28 weeks.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ADX-102 1% Topical Dermal Cream | 0/7 (0%) | 0/7 (0%) | 6/7 (85.7%) |
| Vehicle Topical Dermal Cream | 0/4 (0%) | 0/4 (0%) | 2/4 (50%) |
| Event | ADX-102 1% Topical Dermal Cream | Vehicle Topical Dermal Cream |
|---|---|---|
| PruritusSkin and subcutaneous tissue disorders | 3/7 | 0/4 |
| EosinophiliaBlood and lymphatic system disorders | 2/7 | 0/4 |
| RashSkin and subcutaneous tissue disorders | 1/7 | 1/4 |
| Dermatatitis diaperSkin and subcutaneous tissue disorders | 0/7 | 1/4 |
| HyperhidrosisSkin and subcutaneous tissue disorders | 0/7 | 1/4 |
| HordeolumInfections and infestations | 1/7 | 1/4 |
| InfluenzaInfections and infestations | 0/7 | 1/4 |
| Pharyngitis streptococcalInfections and infestations | 0/7 | 1/4 |
| Pneumonia respiratory syncytial viralInfections and infestations | 0/7 | 1/4 |
| SinusitisInfections and infestations | 0/7 | 1/4 |
| Age, Continuous(years) | ADX-102 1% Topical Dermal Cream | Vehicle Topical Dermal Cream | Total |
|---|---|---|---|
| Mean | 18.1 ± 7.78 | 9.5 ± 6.35 | 15.0 ± 8.21 |
| Sex: Female, Male(Participants) | ADX-102 1% Topical Dermal Cream | Vehicle Topical Dermal Cream | Total |
|---|---|---|---|
| Female | 3 | 3 | 6 |
| Male | 4 | 1 | 5 |
| Ethnicity (NIH/OMB)(Participants) | ADX-102 1% Topical Dermal Cream | Vehicle Topical Dermal Cream | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 2 |
| Not Hispanic or Latino | 6 | 3 | 9 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | ADX-102 1% Topical Dermal Cream | Vehicle Topical Dermal Cream | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Black or African American | 2 | 1 | 3 |
| Native Hawaiian or other Pacific Islander | 0 | 0 | 0 |
| White | 5 | 3 | 8 |
| Other | 0 | 0 | 0 |
| Region of Enrollment(Participants) | ADX-102 1% Topical Dermal Cream | Vehicle Topical Dermal Cream | Total |
|---|---|---|---|
| United States | 7 | 4 | 11 |
| Height(centimeters) | ADX-102 1% Topical Dermal Cream | Vehicle Topical Dermal Cream | Total |
|---|---|---|---|
| Mean | 150.38 ± 24.583 | 125.68 ± 29.287 | 141.39 ± 27.850 |
| Weight(kilograms (kg)) | ADX-102 1% Topical Dermal Cream | Vehicle Topical Dermal Cream | Total |
|---|---|---|---|
| Mean | 48.81 ± 18.708 | 29.18 ± 18.864 | 41.67 ± 20.367 |
| Body Mass Index(kg/m^2) | ADX-102 1% Topical Dermal Cream | Vehicle Topical Dermal Cream | Total |
|---|---|---|---|
| Mean | 20.5 ± 3.36 | 16.8 ± 2.89 | 19.1 ± 3.57 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2018 to primary completion in Jan 2020, 18 months.
Results were first posted in Feb 2023, 3 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Reproxalap
Sjogren-Larsson Syndrome